URSODEOXYCHOLIC ACID IN THE TREATMENT OF ALCOHOLIC LIVER-DISEASE

JN PLEVRIS; PC HAYES; IAD BOUCHIER; John Plevris

URSODEOXYCHOLIC ACID IN THE TREATMENT OF ALCOHOLIC LIVER-DISEASE

JN PLEVRIS^*, PC HAYES, IAD BOUCHIER, John Plevris

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Ursodeoxycholic acid (UDCA) has been shown to improve biochemical tests of cholestasis in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis. We studied the effect of UDCA in 11 patients with alcoholic cirrhosis in a placebo-controlled cross-over trial. After 4 weeks treatment with UDCA (15 mg/kg), a significant fall in bilirubin and gamma-glutamyltranspeptidase (GGT) levels occurred compared with placebo. A significant reduction in alanine aminotransferase (ALT) levels was also detected with UDCA therapy, which suggests that this drug may reduce ongoing hepatic damage in alcoholic liver disease despite continued alcohol abuse. Further trials of UDCA in alcoholic liver disease are clearly indicated.

Original language	English
Pages (from-to)	653-656
Number of pages	4
Journal	European Journal of Gastroenterology & Hepatology
Volume	3
Issue number	9
Publication status	Published - Sept 1991

Keywords / Materials (for Non-textual outputs)

URSODEOXYCHOLIC ACID
ALCOHOLIC LIVER DISEASE

Cite this

@article{14e8a078f6de40d5b755bcbf79a85e8f,

title = "URSODEOXYCHOLIC ACID IN THE TREATMENT OF ALCOHOLIC LIVER-DISEASE",

abstract = "Ursodeoxycholic acid (UDCA) has been shown to improve biochemical tests of cholestasis in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis. We studied the effect of UDCA in 11 patients with alcoholic cirrhosis in a placebo-controlled cross-over trial. After 4 weeks treatment with UDCA (15 mg/kg), a significant fall in bilirubin and gamma-glutamyltranspeptidase (GGT) levels occurred compared with placebo. A significant reduction in alanine aminotransferase (ALT) levels was also detected with UDCA therapy, which suggests that this drug may reduce ongoing hepatic damage in alcoholic liver disease despite continued alcohol abuse. Further trials of UDCA in alcoholic liver disease are clearly indicated.",

keywords = "URSODEOXYCHOLIC ACID, ALCOHOLIC LIVER DISEASE",

author = "JN PLEVRIS and PC HAYES and IAD BOUCHIER and John Plevris",

year = "1991",

month = sep,

language = "English",

volume = "3",

pages = "653--656",

journal = "European Journal of Gastroenterology & Hepatology",

issn = "0954-691X",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - URSODEOXYCHOLIC ACID IN THE TREATMENT OF ALCOHOLIC LIVER-DISEASE

AU - PLEVRIS, JN

AU - HAYES, PC

AU - BOUCHIER, IAD

AU - Plevris, John

PY - 1991/9

Y1 - 1991/9

N2 - Ursodeoxycholic acid (UDCA) has been shown to improve biochemical tests of cholestasis in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis. We studied the effect of UDCA in 11 patients with alcoholic cirrhosis in a placebo-controlled cross-over trial. After 4 weeks treatment with UDCA (15 mg/kg), a significant fall in bilirubin and gamma-glutamyltranspeptidase (GGT) levels occurred compared with placebo. A significant reduction in alanine aminotransferase (ALT) levels was also detected with UDCA therapy, which suggests that this drug may reduce ongoing hepatic damage in alcoholic liver disease despite continued alcohol abuse. Further trials of UDCA in alcoholic liver disease are clearly indicated.

AB - Ursodeoxycholic acid (UDCA) has been shown to improve biochemical tests of cholestasis in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis. We studied the effect of UDCA in 11 patients with alcoholic cirrhosis in a placebo-controlled cross-over trial. After 4 weeks treatment with UDCA (15 mg/kg), a significant fall in bilirubin and gamma-glutamyltranspeptidase (GGT) levels occurred compared with placebo. A significant reduction in alanine aminotransferase (ALT) levels was also detected with UDCA therapy, which suggests that this drug may reduce ongoing hepatic damage in alcoholic liver disease despite continued alcohol abuse. Further trials of UDCA in alcoholic liver disease are clearly indicated.

KW - URSODEOXYCHOLIC ACID

KW - ALCOHOLIC LIVER DISEASE

M3 - Article

SN - 0954-691X

VL - 3

SP - 653

EP - 656

JO - European Journal of Gastroenterology & Hepatology

JF - European Journal of Gastroenterology & Hepatology

IS - 9

ER -

URSODEOXYCHOLIC ACID IN THE TREATMENT OF ALCOHOLIC LIVER-DISEASE

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Fingerprint

Cite this